A new patent application from Kancera lays the foundation for the development of additional drug candidates in the Fractalkine project
Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to further develop a new drug candidate from the patented antagonists, and this is estimated to take about 12 months. The development of this new drug candidate is not expected to affect the planned clinical phase IIa study of KAND567.
In 2018, Kancera has applied for two new patents within the Fractalkine project. In addition to the present application, which covers antagonists of the Fractalkine system, Kancera applied for a patent in May for protection of a new synthesis method for the preparation of this type of future drug. The patent-pending synthesis method can be utilized for the production of both KAND567 and some of the newly patented antagonists.
These two independent products (KAND567 and a future new drug candidate), which are protected by separate patent applications, further enhance Kancera’s opportunities to commercialize the Fractalkine project in several diseases, such as cardiovascular disease, inflammation and cancer.
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, by regulating the immune system, blocking survival signals in the cancer cell and addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institute Science Park in Stockholm and the company employs around 20 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7300 as of March 29th, 2017. FNCA is Kancera’s Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin samt Professor Håkan Mellstedt are board members and Kancera’s scientific advisers.
For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
SE 171 48 Solna
Welcome to visit our home-page; www.kancera.com
This is a translation of a pressrelease from Juli 6th 2018.Back